Takeda’s Livtencity Receives NMPA Approval, a First in China for CMV Infection Treatment
Japanese pharmaceutical company Takeda (TYO: 4502) has received its first market approval from China’s National...
TYO: 4502
Takeda Reinforces Takeda Spark Incubator Program with Expanded Partnerships in China
Takeda (TYO: 4502) has reportedly renewed and expanded a series of partnerships to bolster its...
Takeda’s Takecab Receives NMPA Approval for Helicobacter pylori Eradication in China
Takeda (TYO: 4502), a Japan-based pharmaceutical company, has announced that it has received another indication...
US FDA Approves HutchMed and Takeda’s Fruzaqla for Metastatic Colorectal Cancer Treatment
The US Food and Drug Administration (FDA) has granted approval to HutchMed (NASDAQ: HCM) and...
Takeda Partners with New Horizon Health Technology to Manage Helicobacter pylori in China
At the 6th China International Import Expo (CIIE) in Shanghai, Japan-based Takeda has inked a...
Novartis Seeks Access to Takeda’s Business Records Over Confidentiality Concerns
Swiss pharmaceutical giant Novartis (NYSE: NVS) filed a complaint with a US court last week,...
Takeda’s Global Revenues Grow: Strong Performance in Plasma Therapies and Gastroenterology
Japan-based pharmaceutical giant Takeda (TYO: 4502) has released its financial results for the 6-month period...
Huadong Medicine’s Elahere Accepted for NMPA Review in China for Ovarian Cancer Treatment
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that the National Medical Products Administration...
Belief BioMed Partners with Takeda for BBM-H901 Commercialization in Asia
Shanghai-based gene therapy specialist Belief BioMed Group (BBM) has announced a strategic partnership with Japan’s...
HutchMed and Takeda Submit Fruquintinib NDA for Metastatic CRC in Japan
China-based HutchMed (HKG: 0013, NASDAQ: HCM) has announced that its partner Takeda (TYO: 4502) has...
Takeda Initiates Global Withdrawal of Exkivity Following Phase III Trial Results
Japan-based Takeda (TYO: 4502) has announced the voluntary global withdrawal of its tyrosine kinase inhibitor...
Takeda Receives FDA Approval for Subcutaneous Entyvio as UC Maintenance Therapy
The US Food and Drug Administration (FDA) has granted Japan’s Takeda Pharmaceuticals (TYO: 4502) regulatory...
FDA Accepts Takeda’s Filing for Subcutaneous Entyvio as Maintenance Therapy for Crohn’s Disease
The US Food and Drug Administration (FDA) has accepted a filing from Japan-based Takeda (TYO:...
Takeda Secures Exclusive Rights to ImmunoGen’s Elahere in Japan Through New Agreement
Japanese pharmaceutical company Takeda (TYO: 4502) has entered into an exclusive collaboration and license agreement...
Takeda and BridGene Biosciences Achieve Milestone in Neurodegenerative Disorder Target Identification
A 2021 collaboration between Japan’s Takeda (TYO: 4502) and US-based BridGene Biosciences has successfully reached...
HutchMed Ltd Reports 164% Revenue Growth and Clinical Updates for H1 2023
China-based HutchMed Ltd (NASDAQ: HCM; HKG: 0013) has announced its unaudited financial results for the...
China’s MofCOM Hosts Symposium with Multinational Corporations, Promises Development Opportunities
This week, China’s Ministry of Commerce (MofCOM) convened a symposium attended by representatives from a...
Takeda and HutchMed’s Elunate Study Results Published in The Lancet
Takeda (TYO: 4502) and HutchMed (China) Ltd (HKG: 0013, NASDAQ: HCM) have announced that the...
Takeda and HutchMed’s Fruquintinib Receives Priority Review Status from FDA
Takeda (TYO: 4502) and HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) have provided an update...
Takeda Pharma’s Iclusig Poised for Priority Review by CDE for Leukemia Treatments
The Center for Drug Evaluation (CDE) website has indicated that Takeda Pharma’s (TYO: 4502) Iclusig...